B-Cell Non-Hodgkin’s Lymphoma (NHL): Opportunity Analysis and Forecasts to 2027
B-Cell Non-Hodgkin’s Lymphoma (NHL): Opportunity Analysis and Forecasts to 2027
Summary
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of proliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. B-cell lymphomas comprise approximately 85% of all NHL cases diagnosed in the US, and are a diverse group of blood cancers that arise in the B-cells. This report focuses on the four NHL subtypes that represent the greatest commercial opportunities for drug developers during the forecast period: Diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma (FL), Marginal zone lymphoma (MZL) and Mantle cell lymphoma (MCL).
The B-Cell Non-Hodgkin’s lymphoma (NHL) market is expected to grow from $5.7bn in 2017 to $9.2bn by 2027 across the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan) at a compound annual growth rate (CAGR) of 4.9%. The main driver of the growth will be the rise of Chimeric Antigen Receptor (CAR) T cell therapies.
CAR-T therapies, including the currently marketed Yescarta and Kymriah and the pipeline agent lisocabtagene maraleucel, are expected to result in significant revenues due to premium pricing and clinical benefit in heavily pre-treated patients. Their combined revenues are expected to reach around $2.4bn in 2027.
CAR-T therapies have been highly anticipated in NHL, and they are expected to improve treatment outcomes in heavily-treated patients, an area of major unmet need. While currently only approved for the DLBCL subtype, CAR-T therapies are expected to expand into FL, MZL and MCL, and earlier lines of therapy between 2017 and 2027.
Increasing prevalence, primarily by aging populations and the approval and launch of new branded therapies: lisocabtagene maraleucel, ublituximab with umbralisib, Blincyto, tafasitamab, Venclexta, and enzastaurin will also drive market growth. Additionally, label expansion of currently marketed therapies: Yescarta, Kymriah, Polivy, Revlimid, Calquence, Aliqopa and Imbruvica will further drive growth during the forecast period.
A major barrier for market growth in B-cell NHL, however, will be the increased use of biosimilars and generics, in particular biosimilar rituximab. The branded Rituxan alone brought in around $2.5bn in the US in 2018.
Unmet needs remain in B-cell NHL, which will provide opportunities for developers, including the need for predictive and prognostic biomarkers, better therapies for relapsed or refractory DLBCL, further options in FL for specific patient subsets, and therapies for MCL patients refractory to and relapsed after treatment with Imbruvica.
The report “B-Cell Non-Hodgkin’s Lymphoma (NHL): Opportunity Analysis and Forecasts to 2027” provides an overview of B-cell NHL (FL, MZL, DLBCL and MCL), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. Furthermore, it also provides annualized CLL therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven geographic regions, forecast from 2017 to 2027.
Key topics covered in the report include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the B-cell NHL therapeutics market.
Key Questions Answered:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook